The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ceiling on one of its medications conflicted with federal law.

The company sued last year after the board declared the arthritis drug Enbrel “unaffordable,” which ultimately allowed the state to set a maximum price that patients, pharmacies and state-regulated insurers in Colorado could pay. A federal judge threw out that case in March because Amgen hadn’t yet proven it would suffer any harm.

Enbrel treats six conditions where the immune system attacks the joints, skin or other body parts. In October, the state set roughly the same “fair price” that Medicare reached through its price negotiations, of about $31,000 per year. As of 20

See Full Page